Results 31 to 40 of about 240,836 (199)

Case Report: Isolated homonymous hemianopia after reversal of anticoagulation with andexanet alfa [PDF]

Frontiers in Neurology
PurposeClinical scoring systems have been developed (e.g., CHA2DS2-VASc and HAS-BLED) to aid in the perioperative management of anticoagulation therapy.
Paria Malekahmadi, Dina Abdelsalam, Safa Ibrahim, Andrew Go Lee   +3 more
doaj   +2 more sources

First use of andexanet alfa in the management of massive delayed hemothorax [PDF]

Turkish Journal of Emergency Medicine
In emergency medicine practice, massive hemothorax represents a life-threatening condition in patients with comorbidities. We present the case of a 75-year-old female patient with a massive delayed hemothorax, which developed following a chest injury ...
Miroslaw Kozlowski, Julia Antkiewicz, Anna Choroszewska, Krystian Czolpinski, Pawel Niemynski   +4 more
doaj   +2 more sources

Andexanet alfa therapy showed No increased rate of thromboembolic events in spontaneous intracranial hemorrhage patients: A multicenter electronic health record study

World Neurosurgery: X
Highlights • Intracranial hemorrhage accounts for two out of every three major intracranial hemorrhages.• Systemic anticoagulation is routinely prescribed for prevention of cerebrovascular accidents.• The FDA approved Andexanet alfa to treat life ...
John Vellek, Omar H. Tarawneh, Syed Faraz Kazim, Oluwafemi P. Owodunni, Sophia Arbuiso, Smit Shah, Alis J. Dicpinigaitis, Meic H. Schmidt, Rohini G. McKee, Richard Miskimins, Fawaz Al-Mufti, Christian A. Bowers   +11 more
doaj   +3 more sources

Andexanet alfa - what we know about this promising drug [PDF]

Journal of Education, Health and Sport, 2023
Introduction and purpose. Andexanet alfa (AA) is a recombinant modified version of human activated factor X. It is used as an antidote for apixsaban and rivaroxaban when reversal of anticoagulation due to life-threatening or uncontrolled bleeding is ...
Natalia Ilnicka, Patrycja Zuziak, Maria Sadlik, Daria Matyja, Leila Abod   +4 more
doaj   +2 more sources

Three cases of neutralization of factor Xa inhibitors with andexanet alfa under rotational thromboelastography monitoring

Acute Medicine & Surgery
Background Factor Xa inhibitors are direct oral anticoagulants that are extremely useful in clinical applications, safe, and do not require dose adjustment.
Takeshi Yagi, Reina Kawano, Takuto Tomokage, Ryo Ayata, Yasutaka Koga, Kotaro Kaneda, Motoki Fujita, Nanami Yamanaka, Naomasa Mori, Ryosuke Tsuruta   +9 more
doaj   +2 more sources

Abstract 1122‐000165: Endovascular Intervention for a Thrombotic Adverse Event During Andexanet Alfa Infusion

Stroke: Vascular and Interventional Neurology, 2021
Introduction: Andexanet alfa is the only specific reversal agent for factor Xa inhibitors and received FDA approval in 2018. Here we report an early infusion adverse event in a patient with acute intraventricular hemorrhage (IVH) that received Andexanet ...
Mohammad N Kayyali, Oana M Dumitrascu
doaj   +2 more sources

Difficult Intraoperative Heparinization Following Andexanet Alfa Administration [PDF]

Clinical Practice and Cases in Emergency Medicine, 2019
Direct oral anticoagulants are now commonplace, and reversal agents are recently becoming available. Andexanet alfa (AnXa), approved by the United States Food and Drug Administration in 2018, is a novel decoy molecule that reverses factor Xa inhibitors ...
C. James Watson, Sara L. Zettervall, Matthew M. Hall, Michael Ganetsky   +3 more
doaj   +2 more sources

Reversing factor Xa inhibitors – clinical utility of andexanet alfa

Journal of Blood Medicine, 2017
Scott Kaatz,1 Hardik Bhansali,1 Joseph Gibbs,2 Robert Lavender,3 Charles E Mahan,4 David G Paje5 1Division of Hospital Medicine, 2Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, 3Division of General Internal Medicine, University of ...
Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG   +5 more
doaj   +1 more source

Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa

Blood Advances, 2017
: Direct factor Xa (FXa) inhibitors lack a specific reversal agent for emergencies such as major bleeding or urgent surgery. Andexanet alfa, a modified, catalytically inactive, recombinant human FXa derivative, reverses anticoagulant effect by binding ...
Deborah Siegal, Genmin Lu, Janet M. Leeds, Mark Karbarz, Janice Castillo, Vandana Mathur, Athiwat Hutchaleelaha, Uma Sinha, Michael Kitt, Matt McClure, Stanley J. Hollenbach, John T. Curnutte, Pamela B. Conley, Mark Crowther   +13 more
doaj   +2 more sources

Use of andexanet alfa: A British Society for Haematology position statement. [PDF]

Br J Haematol
British Journal of Haematology, Volume 208, Issue 6, Page 1939-1941, June 2026.
Buka RJ, Arachchillage DJ, Bagot CN, Benson G, Bradbury CA, Curry N, Hunt BJ, Sutton DJ, Thomas MR, Westwood JP, Breen K.   +10 more
europepmc   +2 more sources